RU2007139541A - Производные хромана и хромена и их применение - Google Patents
Производные хромана и хромена и их применение Download PDFInfo
- Publication number
- RU2007139541A RU2007139541A RU2007139541/04A RU2007139541A RU2007139541A RU 2007139541 A RU2007139541 A RU 2007139541A RU 2007139541/04 A RU2007139541/04 A RU 2007139541/04A RU 2007139541 A RU2007139541 A RU 2007139541A RU 2007139541 A RU2007139541 A RU 2007139541A
- Authority
- RU
- Russia
- Prior art keywords
- disorder
- compound
- independently selected
- drug
- compound according
- Prior art date
Links
- 0 *c(c(Cl)cc(F)c1)c1Cl Chemical compound *c(c(Cl)cc(F)c1)c1Cl 0.000 description 1
- QYDLKDJXJDEGNU-UHFFFAOYSA-N CC(C)Oc1cc(F)ccc1-c1cccc2c1OCCC2 Chemical compound CC(C)Oc1cc(F)ccc1-c1cccc2c1OCCC2 QYDLKDJXJDEGNU-UHFFFAOYSA-N 0.000 description 1
- DKKALGNRCHEZSU-HNNXBMFYSA-N CNC[C@H](CC1)Oc2c1cccc2-c(ccc(OC)c1)c1OC Chemical compound CNC[C@H](CC1)Oc2c1cccc2-c(ccc(OC)c1)c1OC DKKALGNRCHEZSU-HNNXBMFYSA-N 0.000 description 1
- HAXJKGYJQUUMQT-UHFFFAOYSA-N COc(c(-c1cccc2c1OCCC2)c1)ccc1F Chemical compound COc(c(-c1cccc2c1OCCC2)c1)ccc1F HAXJKGYJQUUMQT-UHFFFAOYSA-N 0.000 description 1
- FMXVKBORMCGMCQ-CQSZACIVSA-N COc(cc(CO)cc1)c1-c1cccc2c1O[C@@H](CN)CC2 Chemical compound COc(cc(CO)cc1)c1-c1cccc2c1O[C@@H](CN)CC2 FMXVKBORMCGMCQ-CQSZACIVSA-N 0.000 description 1
- FDGJBMXRNPBBNR-UHFFFAOYSA-N Cc(c(F)ccc1C(F)(F)F)c1-c1c2OCCCc2ccc1 Chemical compound Cc(c(F)ccc1C(F)(F)F)c1-c1c2OCCCc2ccc1 FDGJBMXRNPBBNR-UHFFFAOYSA-N 0.000 description 1
- NUECAIMJHZGLJO-UHFFFAOYSA-N Cc(cc1)cc(C)c1-c1c2OCCCc2ccc1 Chemical compound Cc(cc1)cc(C)c1-c1c2OCCCc2ccc1 NUECAIMJHZGLJO-UHFFFAOYSA-N 0.000 description 1
- IMYKXIZFHJRQCX-UHFFFAOYSA-N Cc(ccc(Cl)c1)c1-c1cccc2c1OC(CNC)CC2 Chemical compound Cc(ccc(Cl)c1)c1-c1cccc2c1OC(CNC)CC2 IMYKXIZFHJRQCX-UHFFFAOYSA-N 0.000 description 1
- NJABFUOBPLHAEP-CQSZACIVSA-N Cc1ccccc1-c1c2O[C@@H](CN)CCc2ccc1 Chemical compound Cc1ccccc1-c1c2O[C@@H](CN)CCc2ccc1 NJABFUOBPLHAEP-CQSZACIVSA-N 0.000 description 1
- IWUMAOVDGUODOR-UHFFFAOYSA-N Clc(cccc1)c1-c(c(OCCC1)c1cc1)c1Cl Chemical compound Clc(cccc1)c1-c(c(OCCC1)c1cc1)c1Cl IWUMAOVDGUODOR-UHFFFAOYSA-N 0.000 description 1
- UQSMQCNVGMWBFH-UHFFFAOYSA-N FC(Oc1cc(Cl)c(-c2c3OCCCc3ccc2)c(Cl)c1)(F)F Chemical compound FC(Oc1cc(Cl)c(-c2c3OCCCc3ccc2)c(Cl)c1)(F)F UQSMQCNVGMWBFH-UHFFFAOYSA-N 0.000 description 1
- NYMUBQPHHDEUHX-UHFFFAOYSA-N FC(c(cc1)cc(C(F)(F)F)c1-c1cccc2c1OCCC2)(F)F Chemical compound FC(c(cc1)cc(C(F)(F)F)c1-c1cccc2c1OCCC2)(F)F NYMUBQPHHDEUHX-UHFFFAOYSA-N 0.000 description 1
- SDIDHHZGSNWLLI-UHFFFAOYSA-N Fc(c(-c1c2OCCCc2ccc1)ccc1)c1Cl Chemical compound Fc(c(-c1c2OCCCc2ccc1)ccc1)c1Cl SDIDHHZGSNWLLI-UHFFFAOYSA-N 0.000 description 1
- QFMDNJYLJOILTK-UHFFFAOYSA-N Fc(cc1-c(c(Cl)ccc2)c2Cl)cc2c1OCCC2 Chemical compound Fc(cc1-c(c(Cl)ccc2)c2Cl)cc2c1OCCC2 QFMDNJYLJOILTK-UHFFFAOYSA-N 0.000 description 1
- CFSHFGMVRBSQBH-UHFFFAOYSA-N Fc(cc1-c2cccc(Cl)c2F)cc2c1OCCC2 Chemical compound Fc(cc1-c2cccc(Cl)c2F)cc2c1OCCC2 CFSHFGMVRBSQBH-UHFFFAOYSA-N 0.000 description 1
- BEDBEKQOWHFBSH-UHFFFAOYSA-N Fc1cc(-c(cccc2)c2Cl)c2OCCCc2c1 Chemical compound Fc1cc(-c(cccc2)c2Cl)c2OCCCc2c1 BEDBEKQOWHFBSH-UHFFFAOYSA-N 0.000 description 1
- NFPGLTLQGHDZHP-UHFFFAOYSA-N Fc1cc(-c2cc(Cl)ccc2Cl)c2OCC=Cc2c1 Chemical compound Fc1cc(-c2cc(Cl)ccc2Cl)c2OCC=Cc2c1 NFPGLTLQGHDZHP-UHFFFAOYSA-N 0.000 description 1
- RUUUQPPDFREKIY-UHFFFAOYSA-N Fc1cc(-c2cc(Cl)ccc2Cl)c2OCCCc2c1 Chemical compound Fc1cc(-c2cc(Cl)ccc2Cl)c2OCCCc2c1 RUUUQPPDFREKIY-UHFFFAOYSA-N 0.000 description 1
- UYLCJDYFIPWSKM-UHFFFAOYSA-N NCC(C=C1)Oc(c(-c2ccccc2Cl)c2)c1cc2F Chemical compound NCC(C=C1)Oc(c(-c2ccccc2Cl)c2)c1cc2F UYLCJDYFIPWSKM-UHFFFAOYSA-N 0.000 description 1
- OFZCOFFIXMJCHI-UHFFFAOYSA-N NCC(CC1)Oc2c1cccc2-c1ccccc1 Chemical compound NCC(CC1)Oc2c1cccc2-c1ccccc1 OFZCOFFIXMJCHI-UHFFFAOYSA-N 0.000 description 1
- BNXPDLFCGJFNOG-LLVKDONJSA-N NC[C@@H](CC1)Oc2c1cccc2-c(c(Cl)ccc1)c1Cl Chemical compound NC[C@@H](CC1)Oc2c1cccc2-c(c(Cl)ccc1)c1Cl BNXPDLFCGJFNOG-LLVKDONJSA-N 0.000 description 1
- SORWPBVJFRBEQF-AWEZNQCLSA-N NC[C@H](CC1)Oc(c(-c2ccccc2)c2)c1cc2F Chemical compound NC[C@H](CC1)Oc(c(-c2ccccc2)c2)c1cc2F SORWPBVJFRBEQF-AWEZNQCLSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
- C07D311/20—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 hydrogenated in the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- C07D313/02—Seven-membered rings
- C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
- C07D313/08—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67382005P | 2005-04-22 | 2005-04-22 | |
US60/673,820 | 2005-04-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2007139541A true RU2007139541A (ru) | 2009-05-27 |
Family
ID=36888961
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2007139541/04A RU2007139541A (ru) | 2005-04-22 | 2006-04-21 | Производные хромана и хромена и их применение |
Country Status (19)
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0210397D0 (en) | 2002-05-07 | 2002-06-12 | Ferring Bv | Pharmaceutical formulations |
US20050261347A1 (en) * | 2003-10-24 | 2005-11-24 | Wyeth | Dihydrobenzofuranyl alkanamine derivatives and methods for using same |
US7435837B2 (en) * | 2003-10-24 | 2008-10-14 | Wyeth | Dihydrobenzofuranyl alkanamine derivatives and methods for using same |
GT200500296A (es) * | 2004-10-21 | 2006-10-02 | Sintesis asimetrica de derivados del dehidrobenzofurano | |
GT200500297A (es) * | 2004-10-21 | 2006-10-27 | Sintesis asimetrica de dehidrobenzofuranos sustituidos | |
JP2008538573A (ja) * | 2005-04-22 | 2008-10-30 | ワイス | ベンゾフラニルアルカナミン誘導体およびその5−ht2cアゴニストとしての使用 |
MX2007013151A (es) * | 2005-04-22 | 2008-01-16 | Wyeth Corp | Derivados de benzodioxano y benzodioxolano y usos de los mismos. |
AU2006239910A1 (en) * | 2005-04-22 | 2006-11-02 | Wyeth | Dihydrobenzofuran derivatives and uses thereof |
US20060258713A1 (en) * | 2005-04-22 | 2006-11-16 | Wyeth | Treatment of pain |
EP1871356A1 (en) * | 2005-04-22 | 2008-01-02 | Wyeth a Corporation of the State of Delaware | Dihydrobenzofuran derivatives and uses thereof |
WO2006116149A1 (en) * | 2005-04-22 | 2006-11-02 | Wyeth | New therapeutic combianations for the treatment or prevention of depression |
GT200600164A (es) * | 2005-04-22 | 2007-03-14 | Derivados de dihidrobenzofuranos y usos de los mismos | |
MX2007013163A (es) * | 2005-04-22 | 2008-01-21 | Wyeth Corp | Derivados de cromano y cromeno y usos de los mismos. |
WO2006116221A2 (en) * | 2005-04-22 | 2006-11-02 | Wyeth | Therapeutic combinations for the treatment or prevention of psychotic disorders |
EP1874292A2 (en) * | 2005-04-24 | 2008-01-09 | Wyeth | Methods for modulating bladder function |
WO2007112065A2 (en) * | 2006-03-24 | 2007-10-04 | Wyeth | Methods for treating cognitive and other disorders |
TW200815388A (en) * | 2006-04-18 | 2008-04-01 | Wyeth Corp | Chromane and chromene derivatives and uses thereof |
EP2727585A1 (en) | 2006-05-16 | 2014-05-07 | Takeda Pharmaceutical Company Limited | In-vivo screening method |
CL2007003043A1 (es) * | 2006-10-24 | 2008-05-30 | Wyeth Corp | Compuestos derivados de cromano; composicion farmaceutica que los comprende; y uso para el tratamiento de un trastorno psicotico, bipolar, depresivo y ansiedad entre otros. |
WO2008052088A1 (en) * | 2006-10-25 | 2008-05-02 | Wyeth | Chromane derivatives, synthesis thereof, and intermediates thereto |
CA2988753A1 (en) | 2007-08-06 | 2009-02-12 | Serenity Pharmaceuticals, Llc | Methods and devices for desmopressin drug delivery |
US20100266504A1 (en) | 2007-11-15 | 2010-10-21 | Takahiro Matsumoto | Condensed pyridine derivative and use thereof |
US8914112B2 (en) | 2008-01-23 | 2014-12-16 | Boston Scienctific Neuromodulation Corporation | Methods and systems of treating pancreatitis pain caused by sphincter of Oddi dysfunction |
US8676322B2 (en) | 2008-01-30 | 2014-03-18 | Boston Scientific Neuromodulation Corporation | Methods and systems of treating pancreatitis pain |
JP2010043063A (ja) | 2008-05-09 | 2010-02-25 | Agency For Science Technology & Research | 川崎病の診断及び治療 |
US11963995B2 (en) | 2008-05-21 | 2024-04-23 | Ferring B.V. | Methods comprising desmopressin |
US20100286045A1 (en) | 2008-05-21 | 2010-11-11 | Bjarke Mirner Klein | Methods comprising desmopressin |
EP2296686B2 (en) | 2008-05-21 | 2017-11-01 | Ferring B.V. | Orodispersible desmopressin for increasing initial period of sleep undisturbed by nocturia |
WO2011071136A1 (ja) | 2009-12-11 | 2011-06-16 | アステラス製薬株式会社 | 線維筋痛症治療剤 |
CN101921252B (zh) * | 2010-07-02 | 2012-05-09 | 中国科学院上海有机化学研究所 | 1-氧杂苯并杂环类化合物、合成方法和用途 |
WO2012087289A1 (en) | 2010-12-21 | 2012-06-28 | Colgate-Palmolive Company | Halogenated biphenols as antibacterial agents |
CN109970533B (zh) * | 2012-12-18 | 2022-06-14 | 帝斯曼知识产权资产管理有限公司 | 由(r)-6,10,14-三甲基十五碳-5-烯-2-酮制备的(6r,10r)-6,10,14-三甲基十五烷-2-酮 |
KR101592560B1 (ko) * | 2013-06-21 | 2016-02-05 | 제주대학교 산학협력단 | 신규 플라보노이드 및 그 용도 |
WO2015066344A1 (en) | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
SG11201706515QA (en) | 2015-02-11 | 2017-09-28 | Sunovion Pharmaceuticals Inc | 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders |
EP3494119A4 (en) | 2016-07-29 | 2020-03-25 | Sunovion Pharmaceuticals Inc. | CONNECTIONS AND COMPOSITIONS AND USES THEREOF |
EP3490607A4 (en) | 2016-07-29 | 2020-04-08 | Sunovion Pharmaceuticals Inc. | COMPOUNDS AND COMPOSITIONS, AND USES THEREOF |
EP3661929B1 (en) | 2017-08-02 | 2021-07-14 | Sunovion Pharmaceuticals Inc. | Isochroman compounds and uses thereof |
US20210052600A1 (en) | 2017-12-27 | 2021-02-25 | Takeda Pharmaceutical Company Limited | Therapeutic agents for stress urinary incontinence and incotinence of feces |
WO2020168337A1 (en) * | 2019-02-17 | 2020-08-20 | Magid Abraham | Compositions and methods for treatment of depression and other disorders |
CA3130849A1 (en) | 2019-03-14 | 2020-09-17 | Sunovion Pharmaceuticals Inc. | Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1262078A (en) | 1968-05-24 | 1972-02-02 | Fisons Pharmaceuticals Ltd | Preparation of phenoxy fumaric acid compounds and chromone-2-carboxylic acid compounds therefrom |
US4536518A (en) | 1979-11-01 | 1985-08-20 | Pfizer Inc. | Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine |
US4654362A (en) | 1983-12-05 | 1987-03-31 | Janssen Pharmaceutica, N.V. | Derivatives of 2,2'-iminobisethanol |
GB8814057D0 (en) | 1988-06-14 | 1988-07-20 | Lundbeck & Co As H | New enantiomers & their isolation |
US5089637A (en) | 1990-03-21 | 1992-02-18 | Pfizer Inc. | Process and intermediates for 2r-benzyl-chroman-6-carbaldehyde |
JP3283114B2 (ja) | 1992-09-07 | 2002-05-20 | クミアイ化学工業株式会社 | 縮合ヘテロ環誘導体及び農園芸用殺菌剤 |
US5731324A (en) | 1993-07-22 | 1998-03-24 | Eli Lilly And Company | Glycoprotein IIb/IIIa antagonists |
NZ271995A (en) | 1993-08-19 | 1996-11-26 | Janssen Pharmaceutica Nv | 2-(aminoalkyl)dihydrobenzopyran derivatives; medicaments; and intermediate compounds |
US6150402A (en) | 1994-08-15 | 2000-11-21 | Loma Linda University Medical Center | Natriuretic compounds |
DE4430089A1 (de) | 1994-08-25 | 1996-02-29 | Bayer Ag | Verfahren zur enzymatischen Herstellung von enantiomerenreinen Chroman-2-carbonsäuren und deren Derivaten |
EP0707007B1 (en) | 1994-10-14 | 2001-12-12 | MERCK PATENT GmbH | (R)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]chromane as CNS active agent |
US5658796A (en) | 1995-06-07 | 1997-08-19 | Seprachem, Inc. | Optical resolution of alkyl chroman-2-carboxylates |
CA2276278C (en) | 1997-02-27 | 2009-04-07 | Takeda Chemical Industries, Ltd. | Amine compounds, their production and use |
FR2763335B1 (fr) | 1997-05-16 | 2000-11-24 | Adir | Nouveaux composes heterocycliques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US6133277A (en) | 1997-12-05 | 2000-10-17 | Janssen Pharmaceutica N.V. | (Benzodioxan, benzofuran or benzopyran) derivatives having fundic relaxation properties |
US20060258176A1 (en) * | 1998-02-05 | 2006-11-16 | Asm Japan K.K. | Method for forming insulation film |
US6011035A (en) * | 1998-06-30 | 2000-01-04 | Neuromed Technologies Inc. | Calcium channel blockers |
FR2791675B1 (fr) | 1999-03-30 | 2001-05-04 | Synthelabo | Derives de n-[2-(4-aminophenyl) ethyl] -2,3-dihydro-1,4- benzodioxinne-2-methanamine, leur preparation et leur application en therapeutique |
DE10044091A1 (de) | 2000-09-07 | 2002-04-04 | Merck Patent Gmbh | Chromanonderivate |
UA75898C2 (en) | 2000-11-14 | 2006-06-15 | Merck Patent Gmbh | Method for prophylaxis and treatment of eye diseases using antagonist of integrin receptors |
DE10120619A1 (de) | 2001-04-26 | 2002-10-31 | Merck Patent Gmbh | 2-(5-(4-Fluorphenyl)-3-pyridylmethylaminomethyl-chroman |
CN1536998A (zh) | 2001-08-01 | 2004-10-13 | Ĭ��ר������˾ | 用于治疗眼病的整联蛋白抑制剂 |
EP1432696A1 (en) * | 2001-10-04 | 2004-06-30 | Wyeth | Chroman derivatives as 5-hydroxytryptamine-6 ligands |
WO2003029239A1 (en) * | 2001-10-04 | 2003-04-10 | Wyeth | Chroman and benzofuran derivatives as 5-hydroxytryptamine-6 ligands |
MXPA04003086A (es) | 2001-10-05 | 2004-09-06 | Wyeth Corp | Proceso para sintesis estereoselectiva de 2-hidroximetil-cromanos. |
US6667322B2 (en) | 2001-10-05 | 2003-12-23 | Wyeth | Antidepressant chroman and chromene derivatives of 3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole |
WO2003031428A1 (en) | 2001-10-05 | 2003-04-17 | Wyeth | Stereospecific process for the synthesis of 2-yl chroman derivatives |
US20050014818A1 (en) | 2001-11-09 | 2005-01-20 | Masaru Mitsuda | Process for producing optically active chroman derivative and intermediate |
US7196108B2 (en) | 2002-03-08 | 2007-03-27 | Incyte San Diego Inc. | Bicyclic heterocycles for the treatment of diabetes and other diseases |
AU2003291012A1 (en) | 2002-11-15 | 2004-06-15 | Galileo Pharmaceuticals, Inc. | Chroman derivatives for the reduction of inflammation symptoms |
US7470798B2 (en) | 2003-09-19 | 2008-12-30 | Edison Pharmaceuticals, Inc. | 7,8-bicycloalkyl-chroman derivatives |
DE10348257A1 (de) | 2003-10-16 | 2005-05-25 | Merck Patent Gmbh | Verfahren zur Herstellung von enantiomereneinen in 2-Position substituierten Chromanderivaten |
US20050261347A1 (en) * | 2003-10-24 | 2005-11-24 | Wyeth | Dihydrobenzofuranyl alkanamine derivatives and methods for using same |
US7728155B2 (en) * | 2003-10-24 | 2010-06-01 | Wyeth Llc | Dihydrobenzofuranyl alkanamines and methods for using same as cns agents |
US7435837B2 (en) * | 2003-10-24 | 2008-10-14 | Wyeth | Dihydrobenzofuranyl alkanamine derivatives and methods for using same |
DE102004011265A1 (de) | 2004-03-09 | 2005-09-29 | Lutz F. Prof. Dr. Tietze | Synthese von Vitamin E |
GT200500296A (es) * | 2004-10-21 | 2006-10-02 | Sintesis asimetrica de derivados del dehidrobenzofurano | |
GT200500297A (es) * | 2004-10-21 | 2006-10-27 | Sintesis asimetrica de dehidrobenzofuranos sustituidos | |
CA2588909A1 (en) | 2004-11-24 | 2006-06-22 | Abbott Laboratories | Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor and uses thereof |
MX2007013163A (es) * | 2005-04-22 | 2008-01-21 | Wyeth Corp | Derivados de cromano y cromeno y usos de los mismos. |
WO2006116149A1 (en) * | 2005-04-22 | 2006-11-02 | Wyeth | New therapeutic combianations for the treatment or prevention of depression |
JP2008538573A (ja) * | 2005-04-22 | 2008-10-30 | ワイス | ベンゾフラニルアルカナミン誘導体およびその5−ht2cアゴニストとしての使用 |
MX2007013151A (es) * | 2005-04-22 | 2008-01-16 | Wyeth Corp | Derivados de benzodioxano y benzodioxolano y usos de los mismos. |
WO2006116221A2 (en) * | 2005-04-22 | 2006-11-02 | Wyeth | Therapeutic combinations for the treatment or prevention of psychotic disorders |
AU2006239910A1 (en) * | 2005-04-22 | 2006-11-02 | Wyeth | Dihydrobenzofuran derivatives and uses thereof |
MX2007013179A (es) * | 2005-04-22 | 2008-01-16 | Wyeth Corp | Formas cristalinas de clorhidrato de {[(2r)-7-(diclorofenil)-5- fluoro-2,3-dihidro-1-benzofurano-2-il]metil}amina. |
US20060258713A1 (en) * | 2005-04-22 | 2006-11-16 | Wyeth | Treatment of pain |
AU2006239917A1 (en) * | 2005-04-22 | 2006-11-02 | Wyeth | (7-arlysubstituted 2, 3-dihydr0-1-benz0furan-2-yl) alkylamines in the treatment' of substance abuse |
EP1871356A1 (en) * | 2005-04-22 | 2008-01-02 | Wyeth a Corporation of the State of Delaware | Dihydrobenzofuran derivatives and uses thereof |
EP1874292A2 (en) * | 2005-04-24 | 2008-01-09 | Wyeth | Methods for modulating bladder function |
-
2006
- 2006-04-21 MX MX2007013163A patent/MX2007013163A/es unknown
- 2006-04-21 WO PCT/US2006/015208 patent/WO2006116165A1/en active Application Filing
- 2006-04-21 US US11/409,467 patent/US7365095B2/en not_active Expired - Fee Related
- 2006-04-21 KR KR1020077027247A patent/KR20080008378A/ko not_active Application Discontinuation
- 2006-04-21 AU AU2006239937A patent/AU2006239937A1/en not_active Abandoned
- 2006-04-21 PE PE2006000415A patent/PE20061297A1/es not_active Application Discontinuation
- 2006-04-21 TW TW095114313A patent/TW200716595A/zh unknown
- 2006-04-21 BR BRPI0610027-9A patent/BRPI0610027A2/pt not_active Application Discontinuation
- 2006-04-21 GT GT200600166A patent/GT200600166A/es unknown
- 2006-04-21 AR ARP060101590A patent/AR056320A1/es unknown
- 2006-04-21 EP EP06758490A patent/EP1874756A1/en not_active Withdrawn
- 2006-04-21 JP JP2008507952A patent/JP2008538576A/ja active Pending
- 2006-04-21 CA CA002605587A patent/CA2605587A1/en not_active Abandoned
- 2006-04-21 RU RU2007139541/04A patent/RU2007139541A/ru unknown
- 2006-04-21 CN CNA2006800222674A patent/CN101203505A/zh active Pending
-
2007
- 2007-10-19 ZA ZA200709052A patent/ZA200709052B/xx unknown
- 2007-10-22 CO CO07110959A patent/CO6321153A2/es not_active Application Discontinuation
- 2007-10-22 IL IL186837A patent/IL186837A0/en unknown
- 2007-11-06 NO NO20075641A patent/NO20075641L/no not_active Application Discontinuation
-
2008
- 2008-03-19 US US12/051,368 patent/US20080182891A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
NO20075641L (no) | 2007-11-20 |
EP1874756A1 (en) | 2008-01-09 |
AU2006239937A1 (en) | 2006-11-02 |
TW200716595A (en) | 2007-05-01 |
US20080182891A1 (en) | 2008-07-31 |
WO2006116165A1 (en) | 2006-11-02 |
KR20080008378A (ko) | 2008-01-23 |
GT200600166A (es) | 2007-03-14 |
US7365095B2 (en) | 2008-04-29 |
CN101203505A (zh) | 2008-06-18 |
JP2008538576A (ja) | 2008-10-30 |
BRPI0610027A2 (pt) | 2010-05-18 |
US20060258714A1 (en) | 2006-11-16 |
CO6321153A2 (es) | 2011-09-20 |
CA2605587A1 (en) | 2006-11-02 |
ZA200709052B (en) | 2009-08-26 |
MX2007013163A (es) | 2008-01-21 |
AR056320A1 (es) | 2007-10-03 |
IL186837A0 (en) | 2008-02-09 |
PE20061297A1 (es) | 2006-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2007139541A (ru) | Производные хромана и хромена и их применение | |
RU2007139543A (ru) | Производные бензодиоксана и бензодиоксолана и их применение | |
RU2016143357A (ru) | Органические соединения | |
RU2018130727A (ru) | Органические соединения | |
RU2018137496A (ru) | Органические соединения | |
RU2016143091A (ru) | Органические соединения | |
JP2006143749A5 (US20060258714A1-20061116-C00165.png) | ||
JP2008536946A (ja) | うつ病の処置または予防のための新規の治療的組み合わせ | |
JP2002523508A5 (US20060258714A1-20061116-C00165.png) | ||
AP2002002481A0 (en) | Biaryl ether derivatives useful as monoamine reuptake inhibitors. | |
JP2008538577A (ja) | ジヒドロベンゾフラン誘導体およびその使用 | |
RU2006140964A (ru) | Применение флибансерина для лечения предменструальных и иных сексуальных расстройств у женщин | |
JP2005539068A5 (US20060258714A1-20061116-C00165.png) | ||
BRPI0610028A2 (pt) | combinações terapêuticas para o tratamento ou a prevenção de distúrbios psicóticos | |
JP2002523506A5 (US20060258714A1-20061116-C00165.png) | ||
NZ580801A (en) | Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | |
NZ548926A (en) | Inhibitors of TGF-R signaling for treatment of CNS disorders | |
KR20090036114A (ko) | 무스카린성 수용체 m1 길항제를 이용한 심리 질환 치료 방법 | |
RU2004112546A (ru) | Частичная агонистическая активность в отношении d2 рецепторов допамина и/или ингибирующая активность в отношении норадреналина | |
CN111233731A (zh) | 精神药剂及其用途 | |
BR0317422A (pt) | Compostos de n-(indoletil) cicloamina | |
US20220220062A1 (en) | Synthetic methods of preparing esketamine | |
JP2018508556A5 (US20060258714A1-20061116-C00165.png) | ||
CN102026988B (zh) | 3-取代的丙胺化合物 | |
RU2017134796A (ru) | Органические соединения |